Detalles de la búsqueda
1.
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
N Engl J Med
; 386(18): 1769-1770, 2022 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35507494
2.
Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
J Clin Oncol
; 42(11): 1215-1221, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38412397
3.
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.
Cancers (Basel)
; 16(6)2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539415
4.
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.
JTO Clin Res Rep
; 5(1): 100614, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229766
5.
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
Transl Lung Cancer Res
; 12(7): 1590-1610, 2023 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37577308
6.
Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer.
Am J Pathol
; 179(2): 580-9, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21722621
7.
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Expert Rev Anticancer Ther
; 22(7): 695-702, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35698870
8.
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
Lung Cancer
; 172: 124-126, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36075183
9.
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
Cells
; 10(12)2021 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34944068
10.
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
J Immunother Cancer
; 8(1)2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32581048
11.
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Precis Cancer Med
; 32020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32776005
12.
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
JTO Clin Res Rep
; 1(3)2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34104899
13.
Automated objective determination of percentage of malignant nuclei for mutation testing.
Appl Immunohistochem Mol Morphol
; 22(5): 363-71, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24162261
14.
Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.
Arch Pathol Lab Med
; 137(8): 1063-73, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23899062
15.
A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells.
Arch Pathol Lab Med
; 137(11): 1545-9, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24168492
Resultados
1 -
15
de 15
1
Próxima >
>>